NMB Inhibitors
NMB inhibitors, short for neuromuscular blocking (NMB) inhibitors, belong to a chemical class known for their action on neuromuscular junctions. These compounds are characterized by their ability to interfere with the transmission of signals between nerve endings and muscle fibers. This action is achieved through the modulation of the acetylcholine neurotransmitter system at the neuromuscular junction. The neuromuscular junction is a critical site where motor neuron terminals release acetylcholine to stimulate muscle contraction. NMB inhibitors operate by affecting the receptors in the muscle membrane that would typically bind to acetylcholine, thereby altering the normal electrochemical processes required for muscle contraction.
The chemical structures of NMB inhibitors are diverse, but they share common functional groups that enable them to interact with acetylcholine receptors. There are two primary classes of NMB inhibitors based on their mechanism of action at the receptor site: non-depolarizing and depolarizing. Non-depolarizing NMB inhibitors compete with acetylcholine for the same binding sites on the muscle receptor without activating them, thus preventing the muscle from contracting. This competitive inhibition is often reversible, as the binding of the inhibitor to the receptor is non-covalent. On the other hand, depolarizing NMB inhibitors mimic the action of acetylcholine by binding to the receptor and causing an initial depolarization. However, they do not detach from the receptor as quickly as acetylcholine, leading to a prolonged depolarization of the muscle membrane, which ultimately prevents further muscle contractions. This distinction in mechanism is reflected in their structural diversity and the nature of their interaction with the acetylcholine receptor.
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $63.00 $241.00 | 136 | |
U0126 is a selective inhibitor of MEK1/2, which are part of the MAPK/ERK pathway. By inhibiting this pathway, U0126 can indirectly reduce the signaling leading to NMB-mediated effects, as NMB may play a role in processes modulated by MAPK/ERK activation. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
SB203580 is a p38 MAPK inhibitor that may indirectly decrease NMB activity by blocking downstream pathways that could be involved in NMB-related functions, such as inflammation and stress response. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY294002 is a PI3K inhibitor, which by inhibiting PI3K, can indirectly reduce the activity of NMB by affecting pathways involved in cell survival, proliferation, and migration, potentially influenced by NMB signaling. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Rapamycin is an mTOR inhibitor, which can lead to decreased protein synthesis and cell proliferation. This may indirectly affect NMB activity by modulating cellular processes that are potentially regulated by NMB signaling. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
PD98059 is a selective MEK inhibitor, which indirectly decreases NMB activity by inhibiting the MAPK/ERK signaling pathway, potentially affecting processes where NMB could be involved, such as cell proliferation and differentiation. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $65.00 $267.00 | 257 | |
SP600125 is a JNK inhibitor that may indirectly inhibit NMB by disrupting JNK signaling, which can influence various cellular processes, including apoptosis, which might be modulated by NMB signaling. | ||||||
BML-275 | 866405-64-3 | sc-200689 sc-200689A | 5 mg 25 mg | $94.00 $348.00 | 69 | |
Dorsomorphin is an inhibitor of BMP signaling and may indirectly decrease NMB activity by affecting pathways related to bone morphogenetic proteins, which could intersect with NMB-related pathways in processes like bone formation and repair. | ||||||
NSC 23766 | 733767-34-5 | sc-204823 sc-204823A | 10 mg 50 mg | $148.00 $597.00 | 75 | |
NSC 23766 is an inhibitor of Rac1, which indirectly inhibits NMB by affecting the Rho family GTPases signaling, possibly modulating cytoskeletal reorganization and cell migration where NMB signaling might play a role. | ||||||
Y-27632, free base | 146986-50-7 | sc-3536 sc-3536A | 5 mg 50 mg | $182.00 $693.00 | 88 | |
Y-27632 is a ROCK inhibitor that can indirectly decrease NMB activity by affecting actin cytoskeleton organization and cell contractility, which are cellular processes that could be influenced by NMB signaling. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
Wortmannin is a potent PI3K inhibitor, which by blocking PI3K signaling, indirectly affects NMB activity by potentially modulating cell survival, growth, and migration processes that NMB may influence. | ||||||